Do analysts prefer BVXP or AVCT?

Avacta Group has a consensus target price of GBX 99, suggesting a potential upside of 44.67%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts clearly believe Avacta Group is more favorable than Bioventix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bioventix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has better earnings & valuation, BVXP or AVCT?

Bioventix has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventix £12.54M 6.42 £8.12M £140.52 10.96 Avacta Group £113K 2,837.41 -£30.08M -£9.66 N/A

Is BVXP or AVCT more profitable?

Bioventix has a net margin of 59.30% compared to Avacta Group's net margin of -33,961.06%. Bioventix's return on equity of 65.83% beat Avacta Group's return on equity. Company Net Margins Return on Equity Return on Assets Bioventix 59.30% 65.83% 54.07% Avacta Group -33,961.06% -2,929.47% -21.80%

Do analysts prefer BVXP or PRTC?

PureTech Health has a consensus price target of GBX 508, indicating a potential upside of 304.46%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts plainly believe PureTech Health is more favorable than Bioventix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bioventix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher earnings & valuation, BVXP or PRTC?

Bioventix has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventix £12.54M 6.42 £8.12M £140.52 10.96 PureTech Health £4.66M 65.62 -£91.86M -£46.00 N/A

Which has higher valuation and earnings, ARIX or BVXP?

Arix Bioscience has higher revenue and earnings than Bioventix. Arix Bioscience is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arix Bioscience £14.16M 0.00 £14.96M £0.11 N/A Bioventix £12.54M 6.42 £8.12M £140.52 10.96

Bioventix (BVXP) Competitors

GBX 1,540 -10.00 (-0.65%)

As of 06:45 AM Eastern

Compare

BVXP vs. AVCT, HZD, PRTC, VRP, and ARIX

Should you buy Bioventix stock or one of its competitors? MarketBeat compares Bioventix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bioventix include Avacta Group (AVCT), Horizon Discovery Group plc (HZD.L) (HZD), PureTech Health (PRTC), Verona Pharma plc (VRP.L) (VRP), and Arix Bioscience (ARIX). These companies are all part of the "biotechnology" industry.

How does Bioventix compare to Avacta Group?

Bioventix (LON:BVXP) and Avacta Group (LON:AVCT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Bioventix has a beta of 0.554, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

In the previous week, Bioventix's average media sentiment score of 0.00 equaled Avacta Group'saverage media sentiment score.

Company	Overall Sentiment
Bioventix	Neutral
Avacta Group	Neutral

Avacta Group has a consensus target price of GBX 99, suggesting a potential upside of 44.67%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts clearly believe Avacta Group is more favorable than Bioventix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

20.6% of Bioventix shares are held by institutional investors. Comparatively, 3.1% of Avacta Group shares are held by institutional investors. 6.2% of Bioventix shares are held by company insiders. Comparatively, 47.7% of Avacta Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Bioventix has a net margin of 59.30% compared to Avacta Group's net margin of -33,961.06%. Bioventix's return on equity of 65.83% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventix	59.30%	65.83%	54.07%
Avacta Group	-33,961.06%	-2,929.47%	-21.80%

Bioventix has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventix	£12.54M	6.42	£8.12M	£140.52	10.96
Avacta Group	£113K	2,837.41	-£30.08M	-£9.66	N/A

Summary

Bioventix beats Avacta Group on 8 of the 14 factors compared between the two stocks.

How does Bioventix compare to Horizon Discovery Group plc (HZD.L)?

Horizon Discovery Group plc (HZD.L) (LON:HZD) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

20.6% of Bioventix shares are held by institutional investors. 6.2% of Bioventix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bioventix has lower revenue, but higher earnings than Horizon Discovery Group plc (HZD.L). Horizon Discovery Group plc (HZD.L) is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A
Bioventix	£12.54M	6.42	£8.12M	£140.52	10.96

In the previous week, Horizon Discovery Group plc (HZD.L)'s average media sentiment score of 0.00 equaled Bioventix'saverage media sentiment score.

Company	Overall Sentiment
Horizon Discovery Group plc (HZD.L)	Neutral
Bioventix	Neutral

Bioventix has a net margin of 59.30% compared to Horizon Discovery Group plc (HZD.L)'s net margin of 0.00%. Bioventix's return on equity of 65.83% beat Horizon Discovery Group plc (HZD.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A
Bioventix	59.30%	65.83%	54.07%

Summary

Bioventix beats Horizon Discovery Group plc (HZD.L) on 7 of the 8 factors compared between the two stocks.

How does Bioventix compare to PureTech Health?

Bioventix (LON:BVXP) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

20.6% of Bioventix shares are held by institutional investors. Comparatively, 33.5% of PureTech Health shares are held by institutional investors. 6.2% of Bioventix shares are held by insiders. Comparatively, 13.3% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, PureTech Health had 1 more articles in the media than Bioventix. MarketBeat recorded 1 mentions for PureTech Health and 0 mentions for Bioventix. PureTech Health's average media sentiment score of 1.63 beat Bioventix's score of 0.00 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Bioventix	Neutral
PureTech Health	Very Positive

Bioventix has a net margin of 59.30% compared to PureTech Health's net margin of -2,355.32%. Bioventix's return on equity of 65.83% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventix	59.30%	65.83%	54.07%
PureTech Health	-2,355.32%	-31.98%	-13.39%

Bioventix has a beta of 0.554, meaning that its stock price is 45% less volatile than the broader market. Comparatively, PureTech Health has a beta of 0.793, meaning that its stock price is 21% less volatile than the broader market.

Bioventix has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventix	£12.54M	6.42	£8.12M	£140.52	10.96
PureTech Health	£4.66M	65.62	-£91.86M	-£46.00	N/A

PureTech Health has a consensus price target of GBX 508, indicating a potential upside of 304.46%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts plainly believe PureTech Health is more favorable than Bioventix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

PureTech Health beats Bioventix on 9 of the 16 factors compared between the two stocks.

How does Bioventix compare to Verona Pharma plc (VRP.L)?

Verona Pharma plc (VRP.L) (LON:VRP) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

Bioventix has higher revenue and earnings than Verona Pharma plc (VRP.L). Verona Pharma plc (VRP.L) is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verona Pharma plc (VRP.L)	N/A	N/A	N/A	-£32.70	N/A
Bioventix	£12.54M	6.42	£8.12M	£140.52	10.96

In the previous week, Verona Pharma plc (VRP.L)'s average media sentiment score of 0.00 equaled Bioventix'saverage media sentiment score.

Company	Overall Sentiment
Verona Pharma plc (VRP.L)	Neutral
Bioventix	Neutral

Bioventix has a net margin of 59.30% compared to Verona Pharma plc (VRP.L)'s net margin of 0.00%. Bioventix's return on equity of 65.83% beat Verona Pharma plc (VRP.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verona Pharma plc (VRP.L)	N/A	N/A	N/A
Bioventix	59.30%	65.83%	54.07%

20.6% of Bioventix shares are held by institutional investors. 6.2% of Bioventix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Bioventix beats Verona Pharma plc (VRP.L) on 8 of the 8 factors compared between the two stocks.

How does Bioventix compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

In the previous week, Arix Bioscience's average media sentiment score of 0.00 equaled Bioventix'saverage media sentiment score.

Company	Overall Sentiment
Arix Bioscience	Neutral
Bioventix	Neutral

Arix Bioscience has higher revenue and earnings than Bioventix. Arix Bioscience is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A
Bioventix	£12.54M	6.42	£8.12M	£140.52	10.96

Arix Bioscience has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Bioventix has a beta of 0.554, indicating that its stock price is 45% less volatile than the broader market.

41.3% of Arix Bioscience shares are held by institutional investors. Comparatively, 20.6% of Bioventix shares are held by institutional investors. 20.7% of Arix Bioscience shares are held by insiders. Comparatively, 6.2% of Bioventix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Arix Bioscience has a net margin of 105.64% compared to Bioventix's net margin of 59.30%. Bioventix's return on equity of 65.83% beat Arix Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arix Bioscience	105.64%	6.41%	2.18%
Bioventix	59.30%	65.83%	54.07%

Summary

Arix Bioscience beats Bioventix on 7 of the 10 factors compared between the two stocks.

Get Bioventix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BVXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BVXP vs. The Competition

Export

Metric	Bioventix	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£80.47M	£524.40M	£6.96B	£2.78B
Dividend Yield	9.49%	3.90%	2.68%	6.12%
P/E Ratio	10.96	3.14	27.20	368.15
Price / Sales	6.42	6,506.03	578.26	84,722.19
Price / Cash	30.89	13.13	49.25	27.89
Price / Book	6.70	86.98	10.73	7.49
Net Income	£8.12M	-£96.07M	£3.59B	£5.89B
7 Day Performance	-2.53%	-1.99%	-1.95%	0.03%
1 Month Performance	-9.99%	1.08%	2.19%	-1.36%
1 Year Performance	-44.90%	54.65%	23.80%	62.04%

Bioventix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BVXP Bioventix	N/A	GBX 1,540 -0.6%	N/A	-43.4%	£80.47M	£12.54M	10.96	12
AVCT Avacta Group	N/A	GBX 68.50 -2.8%	GBX 99 +44.5%	+110.1%	£320.96M	£113K	N/A	120
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
PRTC PureTech Health	3.5828 of 5 stars	GBX 120.91 +1.3%	GBX 508 +320.2%	-9.1%	£294.31M	£4.66M	N/A	300	Positive News
VRP Verona Pharma plc (VRP.L)	N/A	N/A	N/A	N/A	£228M	N/A	N/A	22	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:BVXP) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bioventix (BVXP) Competitors

BVXP vs. AVCT, HZD, PRTC, VRP, and ARIX

How does Bioventix compare to Avacta Group?

Summary

How does Bioventix compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does Bioventix compare to PureTech Health?

Summary

How does Bioventix compare to Verona Pharma plc (VRP.L)?

Summary

How does Bioventix compare to Arix Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVXP vs. The Competition

Bioventix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bioventix (BVXP) Competitors

BVXP vs. AVCT, HZD, PRTC, VRP, and ARIX

How does Bioventix compare to Avacta Group?

Which has more risk & volatility, BVXP or AVCT?

Does the media refer more to BVXP or AVCT?

Do analysts prefer BVXP or AVCT?

Do insiders & institutionals believe in BVXP or AVCT?

Is BVXP or AVCT more profitable?

Which has better earnings & valuation, BVXP or AVCT?

Summary

How does Bioventix compare to Horizon Discovery Group plc (HZD.L)?

Do insiders and institutionals hold more shares of HZD or BVXP?

Which has better earnings and valuation, HZD or BVXP?

Does the media favor HZD or BVXP?

Is HZD or BVXP more profitable?

Summary

How does Bioventix compare to PureTech Health?

Do insiders & institutionals believe in BVXP or PRTC?

Does the media favor BVXP or PRTC?

Is BVXP or PRTC more profitable?

Which has more risk and volatility, BVXP or PRTC?

Which has higher earnings & valuation, BVXP or PRTC?

Do analysts prefer BVXP or PRTC?

Summary

How does Bioventix compare to Verona Pharma plc (VRP.L)?

Which has stronger earnings and valuation, VRP or BVXP?

Does the media refer more to VRP or BVXP?

Is VRP or BVXP more profitable?

Do insiders and institutionals have more ownership in VRP or BVXP?

Summary

How does Bioventix compare to Arix Bioscience?

Does the media favor ARIX or BVXP?

Which has higher valuation and earnings, ARIX or BVXP?

Which has more risk and volatility, ARIX or BVXP?

Do insiders & institutionals believe in ARIX or BVXP?

Is ARIX or BVXP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVXP vs. The Competition

Bioventix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools